Theratechnologies (THTX) said Wednesday it acquired exclusive Canadian rights to two investigational RNA-targeted medicines from Ionis Pharmaceuticals (IONS).
The agreement includes olezarsen, which is being evaluated for familial chylomicronemia syndrome and severe hypertriglyceridemia, and donidalorsen, which is being studied for hereditary angioedema treatment.
Theratechnologies will pay Ionis $10 million upfront, with potential milestone payments of up to $12.75 million and tiered double-digit royalties on net sales.
The company said it would oversee regulatory approvals in Canada while Ionis would remain the primary manufacturer. The agreement extends until commercialization ceases or upon earlier termination.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。